$254.75 2.7 1.1%
Last Trade - 09/04/21
| Market Cap | £18.14bn |
| Enterprise Value | £21.48bn |
| Revenue | £10.20bn |
| Position in Universe | 493rd / 6827 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 8,680 | 9,553 | 10,308 | 11,333 | 11,555 | 13,979 | 14,279 | 13,542 | +10.0% | ||
| -16.7 | +43.0 | +1.0 | +40.8 | -6.5 | +103.3 | +9.70 | -27.5 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD). The LCD segment is an independent clinical laboratory business, which offers menu of frequently requested and specialty testing through an integrated network of primary and specialty laboratories across the United States. The CDD segment offers drug development services, and provides a range of drug research and development (R&D) and market access services to biopharmaceutical companies and medical device companies across the world. It serves a range of customers, including managed care organizations (MCOs), biopharmaceutical companies, governmental agencies, physicians and other healthcare providers.
| Last Annual | December 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | March 8, 1994 |
| Public Since | April 24, 1991 |
| No. of Shareholders: | 1,398 |
| No. of Employees: | 72,400 |
| Sector | Healthcare |
| Industry | Healthcare Providers & Services |
| Index | S&P Composite 1500 , S&P 500 , S&P 500 Health Care (sector), |
| Exchange | New York Stock Exchange |
| Shares in Issue | 97,600,000 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | 358 S MAIN ST, BURLINGTON, 27215-5837, United States |
| Web | https://www.labcorp.com |
| Phone | +1 336 2291127 |
| Contact | Clarissa Willett (Vice President, Investor Relations) |
| Auditors | PricewaterhouseCoopers LLP |
As of 09/04/21, shares in Laboratory of America Holdings are trading at $254.75, giving the company a market capitalisation of £18.14bn. This share price information is delayed by 15 minutes.
Shares in Laboratory of America Holdings are currently trading at $254.75 and the price has moved by 73.54% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Laboratory of America Holdings price has moved by 16.97% over the past year.
Of the analysts with advisory recommendations for Laboratory of America Holdings, there are there are currently 6 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Laboratory of America Holdings is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Laboratory of America Holdings is scheduled to issue upcoming financial results on the following dates:
Laboratory of America Holdings does not currently pay a dividend.
Laboratory of America Holdings does not currently pay a dividend.
Laboratory of America Holdings does not currently pay a dividend.
To buy shares in Laboratory of America Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Laboratory of America Holdings are currently trading at $254.75, giving the company a market capitalisation of £18.14bn.
Here are the trading details for Laboratory of America Holdings:
Based on an overall assessment of its quality, value and momentum, Laboratory of America Holdings is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Laboratory of America Holdings are currently priced at $254.75. At that level they are trading at 5.93% discount to the analyst consensus target price of 0.00.
Analysts covering Laboratory of America Holdings currently have a consensus Earnings Per Share (EPS) forecast of 21.345 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Laboratory of America Holdings. Over the past six months, the relative strength of its shares against the market has been 12.25%. At the current price of $254.75, shares in Laboratory of America Holdings are trading at 23.52% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Laboratory of America Holdings PE ratio based on its reported earnings over the past 12 months is 13.09. The shares are currently trading at $254.75.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Laboratory of America Holdings's management team is headed by:
Here are the top five shareholders of Laboratory of America Holdings based on the size of their shareholding:
